CLAIM LISTING

Claim 1 (Currently Amended): A pharmaceutical composition for preventing, treating or managing one or more dermatological skin conditions comprising a therapeutically effective amount of tetrasilver tetroxide~~, or a pharmaceutically acceptable derivative thereof,~~ substantially free of added persulfate, wherein the pharmaceutical composition further comprises a semi-solid or solid carrier medium that adheres to skin.

Claim 2 (Previously Presented): The pharmaceutical composition of claim 1, wherein the therapeutically effective amount is from about 50 ppm to 500,000 ppm.

Claim 3 (Previously Presented): The pharmaceutical composition of claim 1, wherein the therapeutically effective amount is from about 400 ppm to 100,000 ppm.

Claim 4 (Cancelled)

Claim 5 (Previously Presented): The pharmaceutical composition of claim 1, adapted for topical administration and wherein the carrier comprises petroleum jelly.

Claim 6 (Previously Presented): The pharmaceutical composition of claim 1, further comprising a thixotropic agent sufficient to increase adherence of the composition to skin without excessive runoff.

Claim 7 (Previously Presented): The pharmaceutical composition of claim 1, further comprising a powder or a plurality of powder crystals or granules.

Claim 8 (Currently Amended): A method for preventing, treating, or managing one or more dermatological skin diseases in a patient's skin, which comprises administering tetrasilver tetroxide~~, or a pharmaceutically acceptable derivative thereof,~~ which is substantially free of added persulfate, to the skin in an amount and for a period of time which is therapeutically effective to treat such condition(s), wherein the pharmaceutical composition further comprises a semi-solid or solid carrier medium that adheres to skin.

Claim 9 (Previously Presented): The method of claim 8, wherein the therapeutically effective amount is from about 50 ppm to 500,000 ppm, based on the weight of the carrier medium.

Claim 10 (Original): The method of claim 9, wherein the carrier medium comprises petroleum jelly.

Claim 11 (Currently Amended): The method of claim 8, wherein the tetrasilver tetroxide~~, or a pharmaceutically acceptable derivative thereof,~~ is a powder.

Claim 12 (Original): The method of claim 9, wherein the therapeutically effective amount is from about 400 ppm to 100,000 ppm.

Claim 13 (Previously Presented): The method of claim 9, wherein the administering is topical or transdermal.

Claim 14 (Original): The method of claim 13, wherein the composition is topically administered directly to the skin.

Claim 15 (Currently Amended): The method of claim 14, wherein the tetrasilver tetroxide composition~~, or a pharmaceutically acceptable derivative thereof,~~ further comprises a thixotropic agent sufficient to increase adherence of the composition to the skin without excessive runoff.

Claim 16 (Original): The method of claim 14, wherein the skin disease is caused by a non-pathogenic condition comprising one or more of an autoimmune condition, a circulatory condition, or a neurological condition.

Claim 17 (Original): The method of claim 8, wherein the skin disease prevented, treated, or managed comprises at least one of eczema, psoriasis, dermatitis, ulcers, shingles, rashes, bedsores, cold sores, blisters, boils, herpes, acne, pimples, skin chafing, skin cracking, skin itch, skin peeling, heat rashes, leprosy, dermal tuberculosis, and warts.

Claim 18 (Original): The method of claim 17 wherein the skin disease prevented, treated, or managed is one or more of cold sores, herpes, shingles, acne, psoriasis, dermatitis, skin ulcers, heat rashes, leprosy, dermal tuberculosis, or eczema.

Claim 19 (Original): The method of claim 18, wherein the disease is psoriasis, skin ulcers, heat rashes, leprosy, dermal tuberculosis, or atopic dermatitis.

Claim 20 (Currently Amended): The method of claim 8, wherein silver tetroxide~~, or a pharmaceutically acceptable derivative thereof,~~ is completely free of added persulfate.

Claim 21 (Currently Amended): The method of claim 8, wherein the administering comprises application of the tetrasilver tetroxide~~, or a pharmaceutically acceptable derivative thereof,~~ to the skin at a dosage level of about 10 mg to 500 mg per cm^2 of skin surface.

Claim 22 (Currently Amended): The method of claim 8, wherein an [[the]] amount of persulfate is insufficient to cause adverse effects.

Claim 23 (Currently Amended): A method for preventing, treating, or managing one or more non-pathogenic, dermatological skin conditions, which comprises administering tetrasilver tetroxide~~, or a pharmaceutically acceptable derivative thereof,~~ substantially free of added persulfate, to the skin in an amount and for a period of time which is therapeutically effective to treat such condition(s).

Claim 24 (Original): The method of claim 23, wherein the non-pathogenic, dermatological skin condition comprises an autoimmune disorder, a neurological condition, a circulatory condition, or a combination thereof.

Claim 25 (New): The method of claim 23, wherein the non-pathogenic, dermatological skin condition is selected from the group consisting of: eczema, psoriasis, dermatitis, heat rash, skin ulcer, bedsore, blister, boil, skin chafing, skin cracking, skin itch and skin peeling.

Claim 26 (New): A pharmaceutical composition for preventing, treating or managing a non-pathogenic, dermatological skin condition comprising a therapeutically effective amount of tetrasilver tetroxide substantially free of added persulfate, wherein the non-pathogenic, dermatological skin condition is selected from the group consisting of: eczema, psoriasis, dermatitis, heat rash, skin ulcer, bedsore, blister, boil, skin chafing, skin cracking, skin itch and skin peeling.